KMLE
»çÀÌÆ® ¼Ò°³
°Ë»ö
°Ë»ö¾î Áö¿ì±â
´Ý±â
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
°í±Þ °Ë»ö ¼³Á¤
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú :
14
ÆäÀÌÁö:
9
Á¦Ç°¸í
¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¾Æ´Ï½ºÆ¾Á¤
Mequitazine 5 mg
ȯÀÎÁ¦¾à
Àü¹®|±Þ¿©
44¿ø/1 °³
Æå½ÅÁÖ
Pefloxacin Methanesulfonate 558.5
ȯÀÎÁ¦¾à
Àü¹®|»èÁ¦
0¿ø/1 °³
µ¶½ÃÄÚ¸°Á¤
Doxycycline Hyclate 100 mg
ȯÀÎÁ¦¾à
Àü¹®|»èÁ¦
0¿ø/1 °³
Åä¼¼¶ôÁ¤400mg
Micronized Etodolac 400 mg
ȯÀÎÁ¦¾à
Àü¹®|±Þ¿©
377¿ø/1 °³
Æ®¸®¶÷Á¤0.25mg
Triazolam 0.25 mg
ȯÀÎÁ¦¾à
Àü¹®|±Þ¿©
138¿ø/1 °³
Æä³ì½ÉÁ¤ÁÖ1g
Cefmenoxime HCl 1 g
ȯÀÎÁ¦¾à
Àü¹®|»èÁ¦
0¿ø/1 °³
Æä³ì½ÉÁ¤ÁÖ500mg
Cefmenoxime HCl 500 mg
ȯÀÎÁ¦¾à
Àü¹®|»èÁ¦
0¿ø/1 °³
Æå½ºÅ½Á¤
Levofloxacin 100 mg
ȯÀÎÁ¦¾à
Àü¹®|»èÁ¦(ºñ±Þ¿©Àüȯ)
0¿ø/1 °³
Å©·Îº£°Õ¿¡ÀÌÅ©¸²
Betamethasone Valerate 0.61 mg/g, Gentamicin Sulfate 1 mg/g
ȯÀÎÁ¦¾à
ÀϹÝ
³ªº¥Å¹Á¤
Nabumetone 500 mg
ȯÀÎÁ¦¾à
Àü¹®|±Þ¿©
415¿ø/1 °³
¾¾ÇÁ¶÷Á¤
Citalopram Hydrobromide 24.98 mg
ȯÀÎÁ¦¾à
Àü¹®|»èÁ¦
0¿ø/1 °³
µà·¯ºê¿Ü¿ë¾×
Alprostadil 15 mg
ȯÀÎÁ¦¾à
Àü¹®
»ç·ÎŸµå¼¹æÄ¸½¶10mg
Amitriptyline HCl 10 mg
ȯÀÎÁ¦¾à
Àü¹®|»èÁ¦
0¿ø/1 °³
Æø¼¼Æ¾Ä¸½¶10mg
Fluoxetine HCl 11.2 mg
ȯÀÎÁ¦¾à
Àü¹®|±Þ¿©
297¿ø/1 °³
ÀÌÀü
´ÙÀ½
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
9
¿µ¹®
ÇѱÛ
cycloid personality
¼øÈ¯ÇüÀΰÝ
cycloid psychosis
¼øÈ¯ÇüÁ¤½Åº´
cyclomere
µ¹¸²ºÐÀý, ȯ»óüÀý
cyclosis
¼¼Æ÷Áúȯ·ù
cyclothymia
¼øÈ¯±âºÐÀå¾Ö
cyclothymic disorder
¼øÈ¯±âºÐÀå¾Ö
cyclothymic personality
¼øÈ¯±âºÐÀΰÝ
cytapheresis
¼¼Æ÷¼ººÐäÁý(¼ú), ¼¼Æ÷ºÐ¸®±³È¯(¼ú)
cardiovascular disease
½É(Àå)Ç÷°üÁúȯ
cardioversion
½ÉÀåÀ²µ¿Àüȯ
cardioverter
½ÉÀåÀ²µ¿Àüȯ±â
case morbidity rate
Áõ·ÊÀÌȯÀ²
cation exchange
¾çÀ̿±³È¯
cation exchange resin
¾çÀ̿±³È¯¼öÁö
celiac disease
º¹°º´, º¹°Áúȯ
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
9
¿µ¹®
ÇѱÛ
coronary steal
½ÉÀåÇ÷·ùÀüȯ
coronary care unit
½ÉÀ嵿¸ÆÁúȯÁýÁßÄ¡·á½Ç
countercurrent exchange
¿ª·ù±³È¯
countercurrent exchanger system
¿ª·ù±³È¯°è
cremaster muscle
°íȯ¿Ã¸²±Ù
cremasteric fascia
°íȯ¿Ã¸²±Ù¸·
cremasteric reflex
°íȯ¿Ã¸²±Ù¹Ý»ç
critical care medicine
ÁßȯÀÚÀÇÇÐ
critically ill patient
ÁßȯÀÚ
cross circulation
±³Â÷¼øÈ¯
cutaneous disorder
ÇǺÎÁúȯ
cutaneous hallucination
ÇǺÎȯ°¢
cyclic fluctuation
¼øÈ¯º¯È
cyclic periodicity
¼øÈ¯Áֱ⼺
cyclic schizophrenia
¼øÈ¯Á¤½ÅºÐ¿º´
ÀÌÀü
´ÙÀ½
Sponsored Links
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
9
¿µ¹®
ÇѱÛ
anorchia
¹«°íȯ
anorchia congenital
¼±Ãµ¼º ¹«°íȯÁõ.
anorchism
°íȯ°á¿©Áõ
anterior atlanto-occipital membrane
¾ÕȯÃßÈĵθ·, ÀüȯÃßÈĵθ·(îñü» õÐýÔ騝
anterior embryotoxon
¾ÕÅ»ýȯ
antigenic diversion
Ç׿øÀüȯ(ù÷ê«ï®üµ).
antigenic transformation
Ç׿øº¯È¯(ù÷ê«Ü¨üµ).
antihallucinogen
Ç×ȯ°¢Á¦(ù÷ü³ÊÆð¥).
aortic configuration = sabot heart
´ëµ¿¸Æ(ÆÇ¸·Áúȯ) Çü»ó
aortic valvular disease
´ëµ¿¸ÆÆÇÁúȯ(¡òðü´).
aortism
´ëµ¿¸ÆÁúȯ(üÁú)(¡òðü´ô÷òõ).
aphasi(a)c
1. ½Ç¾î(Áõ)ÀÇ. 2. ½Ç¾îÁõȯÀÚ.
apotheter
Á¦´ëȯ³³±â(Á¦´ëȯ³³±â).
appearance time
ÃâÇö½Ã°£(õóúÞãÁÊà) ¼øÈ¯(âàü») .
appendices epididymidis<³ª>
ºÎ°íȯµ¹±â.
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
15
ÆäÀÌÁö:
9
¿µ¹®
ÇѱÛ
fantasy
ȯ»ó(ü³ßÀ)
phantasm
ȯ»ó(ü³ßÌ).
phantom
ȯ»ó(ü³ßÌ).
phantom lover syndrome
ȯ»ó(ü³ßÌ)¿¬ÀÎÁõÈıº
urticaria annularis ³ª
ȯ»ó(ü»ßÒ)µÎµå·¯±â
phantasy =see fantasy
ȯ»ó, °ø»ó.
phantom border
ȯ»ó°æ°è(ü³ßÌÌÑÍ£)
pili annulati
ȯ»ó¹é¸ð
phantom limb phenomenon
ȯ»ó»çÁöÇö»ó(ü³ßÌÞÌò·úÞßÚ)
chromosome, circular
ȯ»ó¿°»öü
genetic map, circular
ȯ»óÀ¯ÀüÀÚÁöµµ
annulus = annular
ȯ»óÀÇ
annulus migrans
ȯ»óÀ̵¿
phantom pregnancy
ȯ»óÀÓ½Å(¡ìôãã).
roseola annularis ³ª
ȯ»óÀå¹ÌÁø(ü»ßÒíùÚ¹òÖ)
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
9
¿µ¹®
ÇѱÛ
appendix testis
°íȯºÎ¼Ó¹°
arcus cornea juvenilis
¿¬¼Ò¼º °¢¸·(æÄá´àõ ÊÇØ¯) ȯ(ü»)
arcus cornea senilis
³ëÀμº °¢¸·(ÒÇìÑàõ ÊÇØ¯) ȯ(ü»)
arcus juvenilis
¿¬¼Òȯ
arcus juvenilis<³ª>
À¯³âȯ(êêæÄü»).
arcus pinguiculus =a. senilis<³ª>
³ëÀΠȯ(ÖÕìÑü»).
arcus senilis
³ë³âȯ, ³ëÀÎȯ
arcus senilis<³ª>
³ëÀΠȯ(ÖÕìÑü»).
argyrophil cells
ÀºÈ¯¿ø¼º ¼¼Æ÷(ëÞü½êªàõ á¬øà)
arm to tongue time test
ÆÈÇô¼øÈ¯½Ã°£½ÃÇè
arm-to-retina circulation time
ÆÈ¸Á¸·¼øÈ¯½Ã°£, ¿Ï-¸Á¸·¼øÈ¯½Ã°£
aromatic ring
¹æÇâÁ·È¯(Û»úÅðéü»).
arteriolopathia hypertonica diffusa<³ª>
¹ü¹ß¼º °íÇ÷¾Ð¼º ³»°ú,¼øÈ¯¼¼µ¿¸Æº´Áõ(ÛñÛ¡àõÍÔúìäâàõá¬ÔÑØæÜ»ñø).
arteriosclerotic heart disease
µ¿¸Æ°æÈ¼º ½ÉÁúȯ(ãýòðü´).
articular circumference<³ª> c. articularis
°üÀý µÑ·¹, °üÀý ȯ»ó¸é(¡ü»ßÒØü).
ÀÌÀü
´ÙÀ½
´ëÇÑ»ýÈÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
9
¿µ¹®
ÇѱÛ
radical substitution
¶óµðÄ® ġȯ(öÇüµ)
reductase
"¸®´ÚÅ×À̽º, ȯ¿øÈ¿¼Ò(ü½êªý£áÈ)"
reduction
"ȯ¿ø(ü½êª), °¨¼Ò(Êõá´)"
Refsum's disease
·¾¼û Áúȯ(òðü´)
respiratory reduction
È£Èí¼º ȯ¿ø(û¼ýåàõü½êª)
retroconversion
¿ªº¯È¯(æ½Ü¨üµ)
ribosomal subunit exchange
¶óÀ̺¸¼Ø ¾Æ´ÜÀ§(ä¬Ó¤êÈ) ±³È¯(Îßüµ)
ribosome exchange
¶óÀ̺¸¼Ø ±³È¯(Îßüµ)
ribosubstitution
¶óÀ̺¸Ä¡È¯(öÇüµ)
rotational base substitution
¼±È¸ ¿°±â ġȯ(àÁüÞç¤ÐñöÇüµ)
Sandhoff's disease
¼¾µµÇÁ Áúȯ(òðü´)
serum converting enzyme
Ç÷û Àüȯ È¿¼Ò(úìôèï®üµý£áÈ)
serum prothrombin conversion accelerator
Ç÷û(úìôè) ÇÁ·ÎÆ®·Òºó ÀüȯÃËÁøÁ¦(ï®üµõµòäð¥)
serum prothrombin converting factor
Ç÷û(úìôè) ÇÁ·ÎÆ®·Òºó ÀüȯÀÎÀÚ(ï®üµì×í)
sickle cell disease
³´¼¼Æ÷(á¬øà)Áúȯ(òðü´)
ÀÌÀü
´ÙÀ½
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
9
¿µ¹®
ÇѱÛ
susceptibility
°¨¼ö¼º, ÀÌȯ¼º, ÀÚÈÀ²
testicle
°íȯ
testicular
°íȯÀÇ
testicular insufficiency
°íȯ±â´ÉºÎÀü(Áõ)
testis
°íȯ
thromboembolic disease
Ç÷Àü»öÀü¼ºÁúȯ
transducer
º¯È¯±â, º¯È¯ÀåÄ¡, Æ®·£½ºµà¼, ŽÃËÀÚ
two dimensional Fourier transform
ÀÌÂ÷¿øÇ»¸®¾îº¯È¯
underlying disease
¿øÁúȯ, ±âÃÊÁúȯ
undescended testes
Á¤·ù°íȯ, ºÒ°Çϰíȯ
urinary diversion
¿ä·ÎÀüȯ¼ú
valve replacement
ÀΰøÆÇġȯ
valvular heart disease
ÆÇ¸·¼º½ÉÁúȯ
ventilation
Åëdz, ȯ±â
vicious circle
¾Ç¼øÈ¯
ÀÌÀü
´ÙÀ½
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú :
5
ÆäÀÌÁö:
9
ÄÚµå
¿µ¹®
ÇѱÛ
B95.7
Other staphylococcus as the cause of diseases classified to other chapters
´Ù¸¥ Àå¿¡¼ ºÐ·ùµÈ ÁúȯÀÇ ¿øÀÎÀ¸·Î¼ÀÇ ±âŸ Æ÷µµ¾Ë±Õ
B95.8
Unspecified staphylococcus as the cause of diseases classified to other chapters
´Ù¸¥ Àå¿¡¼ ºÐ·ùµÈ ÁúȯÀÇ ¿øÀÎÀ¸·Î¼ÀÇ »ó¼¼ºÒ¸íÀÇ Æ÷µµ¾Ë±Õ
B96
Other bacterial agents as the cause of diseases classified to other chapters
´Ù¸¥ Àå¿¡¼ ºÐ·ùµÈ ÁúȯÀÇ ¿øÀÎÀ¸·Î¼ÀÇ ±âŸ ¼¼±Õ¼º °¨¿°¿ø
B96.0
Mycoplasma pneumoniae [M.pneumoniae] as the cause of diseases classified to other chapters
´Ù¸¥ Àå¿¡¼ ºÐ·ùµÈ ÁúȯÀÇ ¿øÀÎÀ¸·Î¼ÀÇ Æó·Å ¹ÌÄÚÇö󽺸¶
B96.1
Klebsiella pneumoniae [K.pneumoniae] as the cause of diseases classified to other chapters
´Ù¸¥ Àå¿¡¼ ºÐ·ùµÈ ÁúȯÀÇ ¿øÀÎÀ¸·Î¼ÀÇ Æó·Å¸·´ë±Õ
ÀÌÀü
´ÙÀ½
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
9
¿µ¹®
ÇѱÛ
¼³¸í
doctor-patient relationship
ÀÇ»ç-ȯÀÚ °ü°è, ÀÇ»ç ȯÀÚ ½Å·Ú °ü°è
duct of epididymis
ºÎ°í ȯ°ü
ductuli efferentes testis
°íȯ ¼öÃâ ¼Ò°ü
ductus efferent
°íȯ ³¯¼¼°ü
ductus epididymis
ºÎ°íȯ °ü, ºÎ°íȯ ü°ü
´ÜÀÏÀÇ °üÀ¸·Î¼ ±× ¼Ó¿¡ °íȯ ¼öÃâ ¼Ò°üÀÇ ²¿ÀÎ ¸»´ÜºÎ°¡ °³±¸ÇÑ´Ù. ±× ²¿ÀÎ ºÎºÐÀÌ ºÎ°íȯÀÇ ´ëºÎºÐÀ» Çü¼ºÇϰí ÀÖ´Ù.
dying patient
ÀÓÁ¾ ȯÀÚ
dyscyclia
¼øÈ¯ Àå¾Ö
dysdiadochokinesia
±æÇ× ¿îµ¿ ¹Ýº¹ °ï¶õÁõ, º¯È¯ ¿îµ¿ °ï¶õÁõ
ecdemic
À̼Ҽº ÁúȯÀÇ
º´º¯À» ÀÎÁöÇÏ´Â ºÎÀ§·ÎºÎÅÍ ¶³¾îÁ® ÀÖ´Â °÷¿¡ ¿øÀÎÀÌ Á¸ÀçÇÏ´Â Áúȯ¿¡ °üÇØ¼ »ç¿ëÇÑ´Ù.
eH
»êÈ È¯¿ø ÀüÀ§ ºÎÈ£
elderly patient
³ëÀΠȯÀÚ
encephalopathy
³ú Áúȯ, ³ú º´º¯
º¯¼ºÀ» ÀÏÀ¸Å°´Â ³ú Áúȯ.
environmental chemotactic factor
ȯ°æ¼º ÈÇÐ ÁÖ¼º ÀÎÀÚ
environmental contingency
ȯ°æ ¿äÀÎ
environmental damage
ȯ°æ ÇÇÇØ
ÀÌÀü
´ÙÀ½
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú:
10
ÆäÀÌÁö:
9
ȯÀÎŰ´©ÇÁ¸±Á¤
A09701921
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Quinupramine
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | ±Þ¿©
À¯¶õŹÁÖ100mg
A09701831
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Ranitidine HCl
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | ±Þ¿© | ºÐ¾÷¿¹¿ÜÀǾàǰ
À¯¶õŹÁ¤150mg
A09701741
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Ranitidine HCl
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | ±Þ¿©
À¯¶õŹÁ¤300mg
A09701821
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Ranitidine HCl
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | »èÁ¦
À¯¶õŹÁÖ
A09701771
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Ranitidine HCl
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | ±Þ¿© | ºÐ¾÷¿¹¿ÜÀǾàǰ
·Ï½º·Î½ÅÁ¤
A09703541
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Roxithromycin
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | »èÁ¦
½êƾÁ¤
A09701391
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Serratiopeptidase
±¸ºÐ/º¸Çè±Þ¿©: ÀϹÝÀǾàǰ | »èÁ¦
½Ç¹Ý¿¬°í
A09701131
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Silver Sulfadiazine
±¸ºÐ/º¸Çè±Þ¿©: ÀϹÝÀǾàǰ | »èÁ¦
¾Æ·»µåÁ¤
A09703641
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Sodium alendronate
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | ±Þ¿©
¾Æ·»µåÁ¤5mg
A09703631
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Sodium alendronate
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | ±Þ¿©
ÀÌÀü
´ÙÀ½
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú :
15
ÆäÀÌÁö:
9
¿µ¹®
ÇѱÛ
welcome
ȯ¿µ(Àλç)
illusion
ȯ¿µ;ȯ»ó;Âø°¢;¿ÀÇØ;¹Ì¸Á;Åõ¸íÇÑ ¸íÁÖ¸Á»ç(¿©¼º¿ë º£Àϵ ¾²ÀÌ´Â
welcome
ȯ¿µ¹Þ´Â
welcome
ȯ¿µ¹Þ´Â;°í¸¶¿î;¸¶À½´ë·Î ...ÇÒ ¼ö ÀÖ´Â(to);and ~ ±×°ÍÀ¸·Î µÆ´Ù
blowin
ȯ¿µ¹ÞÁö ¸øÇÏ´Â ½ÅÂüÀÚ;Ÿ°ü »ç¶÷
unwelcome
ȯ¿µ¹ÞÁö ¸øÇÏ´Â;´Þ°©Áö ¾ÊÀº;½ÈÀº
visionary
ȯ¿µÀ» º¸´Â »ç¶÷;°ø»ó°¡
phantasmic
ȯ¿µÀÇ
illusional
ȯ¿µÀÇ,ȯ»óÀÇ,Âø°¢ÀÇ
salutatory
ȯ¿µÀÇ. °³È¸ÀλçÀÇ.
visionary
ȯ¿µÀÇ; °¡°øÀûÀÎ
welcome
ȯ¿µÇÏ´Ù
reductor
ȯ¿ø ÀåÄ¡
heme
ȯ¿ø Ç츶ƾ(Çì¸ð±Û·ÎºóÀÇ »ö¼Ò ¼ººÐ)
reduction formula
ȯ¿ø(ȯ»ê) °ø½Ä
ÀÌÀü
´ÙÀ½
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
9
¿µ¹®
ÇѱÛ
Earnings Related Supplement
(¿µ)º¸Çè ±ÞºÎ±Ý(¿µ±¹ÀÇ »çȸº¸ÀåÁ¦µµ¿¡¼ 6°³¿ù°£ ½Ç¾÷ÀÚ(ȯÀÚ)¿¡°Ô Àü³âµµ ¼Òµæ¿¡ µû¶ó Áö±ÞµÊ)
Earth Day
Áö±¸ÀÇ ³¯(ȯ°æ º¸È£Àdz¯,4¿ù 22ÀÏ)
Earth Week
Áö±¸(º¸È£)ÁÖ°£(ȯ°æ º¸È£ÀÇ ÁÖ°£,1971³â 4¿ù 18-24ÀÏ¿¡ ½Ç½Ã)
Earthwatch
Áö±¸ °¨½Ã¸Á(¼¼°èÀû ±Ô¸ð·Î ȯ°æ ¿À¿°À» °¨½ÃÇϱâ À§ÇØ ¸¸µé¾îÁø °Í)
Easter cycle
ºÎȰÀý ¼øÈ¯±â
Eniwetok
¿¡´Ï¿þ·Ï ȯÃÊ(¹Ì±¹ÀÇ ¿øÆø ½ÇÇèÁö)
Environmental Protection Agency
(¹Ì)ȯ°æ º¸È£±¹
Euroclear
À¯·´ ½ÃÀåÀÇ ¾îÀ½ ±³È¯¼Ò
FOE
Friends of the Earth Áö±¸ÀÇ ¹þ(±¹Á¦ ȯ°æº¸È£ ´Üü)
Fun City
ȯ¶ôÀÇ µµ½Ã
Green Panther
¤¼;ÀüÅõÀûÀÎ(¶°µé½âÇÑ,¼º°¡½Å)ȯ°æ º¸È£ ¿îµ¿°¡
Green Party
³ì»ö´ç(¿øÀÚ·Â ¹ßÀü ¹Ý´ë,ȯ°æ º¸È£µîÀ» ÁÖÀå)
Greenpeace
±×¸°Çǽº(ÇÙ½ÇÇè,Æ÷°æ ¹Ý´ë,ȯ°æ º¸È£¸¦ ÁÖÀåÇÏ´Â ±¹Á¦ ´Üü)
Grimm's law
±×¸²ÀÇ ¹ýÄ¢(Jakob GrimmÀÌ ¹ß°ßÇÑ ÀεµÀ¯·Æ¾îÀÇ ÀÚÀ½ ÀüȯÀÇ ¹ýÄ¡)
Hashimoto's disease
ÇϽø𵵺´;¸¸¼º °©»ó¼±¿°(°©»ó¼± ±â´ÉÀÌ ÀúÇϵǴ Áúȯ)
ÀÌÀü
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
9
Á¦Ç°¸í
¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
ÀÌÀü
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
9
ÀÌÀü
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
9
ÀÌÀü
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
9
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
9
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
9
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
9
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
9
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
9
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
9
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
9
¿µ¹®
ÇѱÛ
ÇÑÀÚ
ÀÌÀü
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
9
¿µ¹®
ÇѱÛ
ÇÑÀÚ
ÀÌÀü
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
9
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
9
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑ»ýÈÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
9
¿µ¹®
ÇѱÛ
ÀÌÀü
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
9
¿µ¹®
ÇѱÛ
ÀÌÀü
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
9
ÀÌÀü
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
9
ÀÌÀü
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
9
ÄÚµå
¿µ¹®
ÇѱÛ
ÀÌÀü
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
9
¿µ¹®
ÇѱÛ
¼³¸í
ÀÌÀü
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú:
0
ÆäÀÌÁö:
9
ÀÌÀü
ÅëÇÕ°Ë»ö ¿Ï·á
ÀÌÀü
´ÙÀ½